TSC1 Cancer Research Results

TSC1, tuberous sclerosis 1: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
The TSC1 gene, located on chromosome 9, encodes a protein called hamartin, which plays a crucial role in regulating cell growth and proliferation. Mutations in the TSC1 gene are associated with tuberous sclerosis complex (TSC), a genetic disorder characterized by the development of benign tumors in various organs.

TSC1 (hamartin) and TSC2 (tuberin) form a complex that plays a critical role in regulating the mTOR (mechanistic target of rapamycin) pathway.
• The TSC1/TSC2 complex acts as a negative regulator of mTOR signaling; when active, it helps suppress cell growth and proliferation.

TSC1 and TSC2 serve as tumor suppressors.
TSC1 and TSC2 are not overexpressed in cancer; they are typically involved in loss-of-function scenarios that lead to tumorigenesis.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
100- QC,    Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓, TumCCA↑, chemoPv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

BCR↓, 1,   CDC16↓, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   cMyc↓, 1,  

Cell Death ⓘ

CBP↑, 1,  

Kinase & Signal Transduction ⓘ

CDC7↓, 1,   HER2/EBBR2↓, 1,   TSC2↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   CUL4B↑, 1,   P53↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   cycF↓, 1,   E2Fs↓, 1,   P21↑, 1,   RB1↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

cDC2↓, 1,   EP300↑, 1,   NF2↑, 1,   PTEN↑, 1,  

Migration ⓘ

CDK4/6↓, 1,   MSH2↑, 1,   TSC1↑, 1,  

Clinical Biomarkers ⓘ

BRCA1↑, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,   TGFβR1↑, 1,  
Total Targets: 31

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TSC1, tuberous sclerosis 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:318  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page